Englander Institute for Precision Medicine
Found 797 results
Author Title Type [ Year(Asc)]
Filters: Corrigendum-whole-genome-and-transcriptome-analysis-pancreatic-acinar-cell-carcinoma is   [Clear All Filters]
2024
Al-Ishaq RKhalid, Ferrara CR, Stephan N, Krumsiek J, Suhre K, Montrose DC.  2024.  A Comprehensive Metabolomic and Microbial Analysis Following Dietary Amino Acid Reduction in Mice.. Metabolites. 14(12)
Izadmehr S, Fernandez-Hernandez H, Wiredja D, Kirschenbaum A, Lee-Poturalski C, Tavassoli P, Yao S, Schlatzer D, Hoon D, Difeo A et al..  2024.  Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis.. bioRxiv.
Siew K, Nestler KA, Nelson C, D'Ambrosio V, Zhong C, Li Z, Grillo A, Wan ER, Patel V, Overbey E et al..  2024.  Cosmic kidney disease: an integrated pan-omic, physiological and morphological study into spaceflight-induced renal dysfunction.. Nat Commun. 15(1):4923.
Lira MCecilia, Galluzzi L, Vanpouille-Box C.  2024.  COX2-dependent suppression of anticancer immunity.. Trends Cancer.
Noch EK, Palma L, Yim I, Bullen N, Barnett D, Walsh A, Bhinder B, Benedetti E, Krumsiek J, Gurvitch J et al..  2024.  Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production.. Proc Natl Acad Sci U S A. 121(8):e2317343121.
Beltrán-Visiedo M, Del Valle ASerrano-, Jiménez-Aldúan N, Soler-Agesta R, Naval J, Galluzzi L, Marzo I.  2024.  Cytofluorometric assessment of calreticulin exposure on CD38+ plasma cells from the human bone marrow.. Methods Cell Biol. 189:189-206.
Uemura M, Kikukawa H, Hashimoto Y, Uemura H, Mizokami A, Kato M, Matsushima H, Kosaka T, Nakamura M, Fukasawa S et al..  2024.  Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.. Cancer Med. 13(21):e70029.
Markowitz GJ, Ban Y, Tavarez DA, Yoffe L, Podaza E, He Y, Martin MT, Crowley MJP, Sandoval TA, Gao D et al..  2024.  Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve immunotherapy.. Nat Immunol. 25(10):1884-1899.
Ohara K, Assaad MAl, McNulty SN, Alnajar H, Sboner A, Wilkes DC, He F, Xiang JZhaoying, Mathew S, Elemento O et al..  2024.  Detection of rare and novel gene fusions in patients with diffuse glioma: An institutional retrospective study.. J Neuropathol Exp Neurol.
Klomp JE, J Diehl N, Klomp JA, A Edwards C, Yang R, Morales AJ, Taylor KE, Drizyte-Miller K, Bryant KL, Schaefer A et al..  2024.  Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.. Science. 384(6700):eadk0850.
Greenberg JA, Shah Y, Ivanov NA, Marshall T, Kulm S, Williams J, Tran C, Scognamiglio T, Heymann JJ, Lee-Saxton YJoo et al..  2024.  Developing a predictive model for metastatic potential in pancreatic neuroendocrine tumor.. J Clin Endocrinol Metab.
Forbes ANeil, Xu D, Cohen S, Pancholi P, Khurana E.  2024.  Discovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data.. Cell Syst.
McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GHo, Walch H, Aveson VG, Falvo DJ et al..  2024.  Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.. Cancer Cell. 42(9):1614-1629.e5.
Risnik D, Colado A, Podaza E.  2024.  Editorial: Myeloid cell reprogramming: molecular pathways involved in disease development.. Front Immunol. 15:1414482.
Shore ND, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Tombal B, Nordquist L, Cookson M, Verholen F et al..  2024.  Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.. Oncologist. 29(3):235-243.
Windon A, Assaad MAl, Hadi K, Mendelson N, Hissong E, Deshpande A, Tranquille M, Mclee J, Levine MF, Patel M et al..  2024.  Emerging molecular phenotypes and potential therapeutic targets in esophageal and gastric adenocarcinoma unearthed by whole genome and transcriptome analyses.. Pathol Res Pract. 266:155788.
Assaad MAl, Hadi K, Tu J, Levine MF, Patel M, Deshpande A, Manohar J, Sigouros M, Sboner A, Chapman-Davis E et al..  2024.  Enhancing the detection of clinically relevant biomarkers in advanced uterine and tubo-ovarian carcinomas through genome-wide analysis.. Pathol Res Pract. 266:155773.
Cicin I, Plimack ER, Gurney H, Leibowitz R, Alekseev BY, Parnis FX, Peer A, Necchi A, Bellmunt J, Nishiyama H et al..  2024.  Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.. BMC Cancer. 23(Suppl 1):1256.
Mack TM, Raddatz MA, Pershad Y, Nachun DC, Taylor KD, Guo X, Shuldiner AR, O'Connell JR, Kenny EE, Loos RJF et al..  2024.  Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate.. Nat Aging.
Galassi C, Esteller M, Vitale I, Galluzzi L.  2024.  Epigenetic control of immunoevasion in cancer stem cells.. Trends Cancer.
Spada S, Galluzzi L.  2024.  Epigenetic regulation of cancer.. Int Rev Cell Mol Biol. 383:xi-xv.
Spada S, Galluzzi L.  2024.  Epigenetic regulation of cancer.. Int Rev Cell Mol Biol. 387:xiii-xvii.
Stenzl A, Armstrong AJ, Rogers E, Habr D, Walz J, Gleave M, Sboner A, Ghith J, Serfass L, Schuler KW et al..  2024.  Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists.. Urol Pract. :101097UPJ0000000000000740.
Ohara K, Rendeiro AFigueiredo, Bhinder B, Eng KWha, Ravichandran H, Nguyen D, Pisapia D, Vosoughi A, Fernandez E, Shohdy KS et al..  2024.  The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.. Nat Commun. 15(1):2009.
Sternberg CN, Loriot Y, Choy E, Castellano D, Lopez-Rios F, Banna GLuigi, Zengerling F, De Giorgi U, Gedye C, Masini C et al..  2024.  Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.. Eur Urol Focus.